Reverbio is building a new kind of health monitoring platform—one designed to bring lab-quality biomarker testing into the home, without painful needles or clinic visits. Our early-stage research focuses on interstitial fluid (ISF), an underused yet highly informative medium that reflects many of the biomarkers found through blood draws. By combining hydrogel microneedle patches, MEMS biosensors, and machine learning interpretation, we aim to make frequent, accessible testing possible for people managing chronic conditions and those working to optimize their lifestyle, performance, and overall health.

Our platform is currently in development. It’s not yet commercially available, but our prototypes and early data are laying the foundation for a more decentralized and equitable approach to diagnostics. By removing the logistical, financial, and psychological barriers associated with traditional testing, we hope to empower more people with timely, meaningful health insights that support better everyday decision-making.

Reverbio is a pre–seed stage company, actively engaged in research, validation, and partnership-building. We welcome conversations with potential funders, collaborators, and advisors who share our vision for accessible, user-friendly health technology that puts actionable data into the hands of the people who need it most.